

1995

USP 23


NF 18

THE UNITED STATES PHARMACOPEIA

THE NATIONAL FORMULARY

*By authority of the United States Pharmacopeial Convention, Inc., meeting at Washington, D.C., March 8-10, 1990. Prepared by the Committee of Revision and published by the Board of Trustees*

*Official from January 1, 1995*



UNITED STATES PHARMACOPEIAL CONVENTION, INC.  
12601 Twinbrook Parkway Rockville, MD 20852

**DOCKET**  
**A L A R M**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

## NOTICE AND WARNING

### *Concerning U.S. Patent or Trademark Rights*

The inclusion in the Pharmacopeia or in the National Formulary of a monograph on any drug in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner.

### *Concerning Use of USP or NF Text*

Attention is called to the fact that USP and NF text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Secretary of the USPC Board of Trustees.

© 1994 The United States Pharmacopeial Convention, Inc.  
12601 Twinbrook Parkway, Rockville, MD 20852.  
*All rights reserved*  
ISSN 0195-7996  
ISBN 0-913595-76-4 (cloth)  
0-913595-81-0 (leather)

Printed by Rand McNally, 1133 County Street, Taunton, MA 02780-3795

# Contents

## USP 23

### People

Officers of the Convention .....	v
Board of Trustees .....	v
General Committee of Revision ....	v
Executive Committee of Revision ..	vii
USP Drug Nomenclature Committee .....	vii
Drug Standards Division Executive Committee and Subcommittees .....	vii
USP Reference Standards Committee .....	viii
USP-FDA Joint Committee on Bioequivalence .....	viii
USP-FDA Antibiotic Monograph Subcommittee .....	viii
Drug Standards Division Panels ....	viii
Drug Information Division Executive Committee .....	ix
Drug Information Division Advisory Panels .....	ix
Assistants During 1990-1995 .....	xii
Members of the United States Pharmacopeial Convention .....	xiv

### Preamble

Articles of Incorporation .....	xxii
Constitution and Bylaws .....	xxiii
Rules and Procedures .....	xxxi
USPC Communications Policy.....	xxxvi
USPC Document Disclosure Policy .....	xxxvii
Proceedings .....	xxxix
History of the Pharmacopeia of the United States .....	xliv
Preface to USP 23 .....	liii

### Admissions

Articles Admitted to <i>USP XXII</i> and <i>NF XVII</i> by Supplement ..	xlvi
New Admissions to the Official Compendia .....	xlvi
Official Titles Changed by Supplement .....	xlvi
Changes in Official Titles .....	xlvi
Articles Included in <i>USP XXII</i> but Not Included in <i>USP 23</i> or in <i>NF 18</i> .....	xlvi
Articles Included in <i>NF XVII</i> but Not Included in <i>NF 18</i> or in <i>USP 23</i> .....	1

### Notices

General Notices and Requirements .....	1
---	---

### Monographs

Official Monographs for USP 23 .....	15
---	----

### General Chapters

<i>see page 1648 for detailed contents</i>	
General Tests and Assays .....	1650
General Requirements for Tests and Assays .....	1650
Apparatus for Tests and Assays .....	1673
Microbiological Tests .....	1681
Biological Tests and Assays ....	1690
Chemical Tests and Assays .....	1721
Physical Tests and Determinations .....	1760
General Information .....	1845

### Reagents

Reagents .....	1987
Indicators and Indicator Test Papers .....	2047
Solutions .....	2049
Buffer Solutions .....	2049
Colorimetric Solutions .....	2050
Test Solutions .....	2050
Volumetric Solutions .....	2057

### Tables

Containers for Dispensing Capsules and Tablets .....	2065
Description and Relative Solubility of USP and NF Articles .....	2071
Approximate Solubilities of USP and NF Articles .....	2116
Atomic Weights .....	2123
Alcoholometric Table .....	2126
Thermometric Equivalents .....	2127

# NUTRITIONAL SUPPLEMENTS

**Monographs** Official Monographs ..... 2129

**General Chapters** *see page 2179 for detailed contents*  
General Tests and Assays ..... 2180

## NF 18

**People** See *USP 23*, page v

**Preamble** History of the National Formulary ..... 2196  
Preface to NF 18 ..... 2201

**Admissions** Articles Official in NF 18 ..... 2203

**Tables** USP and NF Pharmaceutic Ingredients, Listed by Categories ..... 2205  
See also *USP 23*, page 2065

**Notices** General Notices and Requirements ..... 2208

**Monographs** Official Monographs for NF 18 .... 2209

**General** *see page 1648 for detailed contents*  
General Tests and Assays See *USP 23*, page 1650  
General Information See *USP 23*, page 1845

**Reagents** Reagents See *USP 23*, page 1987  
Indicators and Indicator Test Papers See *USP 23*, page 2047  
Solutions See *USP 23*, page 2049

**Index** Combined Index to *USP 23* and NF 18 ..... 2321

**Procedure**—Place in the dry flask a quantity of the substance, weighed accurately to the nearest centigram, which is expected to yield 2 to 4 mL of water. If the substance is of a pasty character, weigh it in a boat of metal foil of a size that will just pass through the neck of the flask. If the substance is likely to cause bumping, add enough dry, washed sand to cover the bottom of the flask, or a number of capillary melting-point tubes, about 100 mm in length, sealed at the upper end. Place about 200 mL of toluene in the flask, connect the apparatus, and fill the receiving tube *E* with toluene poured through the top of the condenser. Heat the flask gently for 15 minutes and, when the toluene begins to boil, distil at the rate of about 2 drops per second until most of the water has passed over, then increase the rate of distillation to about 4 drops per second. When the water has apparently all distilled over, rinse the inside of the condenser tube with toluene while brushing down the tube with a tube brush attached to a copper wire and saturated with toluene. Continue the distillation for 5 minutes, then remove the heat, and allow the receiving tube to cool to room temperature. If any droplets of water adhere to the walls of the receiving tube, scrub them down with a brush consisting of a rubber band wrapped around a copper wire and wetted with toluene. When the water and toluene have separated completely, read the volume of water, and calculate the percentage that was present in the substance.

### METHOD III (GRAVIMETRIC)

**Procedure for Chemicals**—Proceed as directed in the individual monograph preparing the chemical as directed under *Loss on Drying* (731).

**Procedure for Biologics**—Proceed as directed in the individual monograph.

**Procedure for Vegetable Drugs**—Place about 10 g of the drug, prepared as directed (see *Vegetable Drugs—Methods of Analysis* (561)) and accurately weighed, in a tared evaporating dish. Dry at 105° for 5 hours, and weigh. Continue the drying and weighing at 1-hour intervals until the difference between two successive weighings corresponds to not more than 0.25%.

## (941) X-RAY DIFFRACTION

Every crystal form of a compound produces its own characteristic X-ray diffraction pattern. These diffraction patterns can be derived either from a single crystal or from a powdered specimen (containing numerous crystals) of the material. The spacings between and the relative intensities of the diffracted maxima can be used for qualitative and quantitative analysis of crystalline materials. Powder diffraction techniques are most commonly employed for routine identification and the determination of relative purity of crystalline materials. Small amounts of impurity, however, are not normally detectable by the X-ray diffraction method, and for quantitative measurements it is necessary to prepare the sample carefully to avoid preferred orientation effects.

The powder methods provide an advantage over other means of analysis in that they are usually nondestructive in nature (specimen preparation is usually limited to grinding to ensure a randomly oriented sample, and deleterious effects of X-rays on solid pharmaceutical compounds are not commonly encountered). The principal use of single-crystal diffraction data is for the determination of molecular weights and analysis of crystal structures at the atomic level. However, diffraction established for a single crystal can be used to support a specific powder pattern as being truly representative of a single phase.

**Solids**—A solid substance can be classified as being crystalline, noncrystalline, or a mixture of the two forms. In crystalline materials, the molecular or atomic species are ordered in a three-dimensional array, called a lattice, within the solid particles. This ordering of molecular components is lacking in noncrystalline material. Noncrystalline solids sometimes are referred to as glasses or amorphous solids when repetitive order is nonexistent in all three dimensions. It is also possible for order to exist in only one or two dimensions, resulting in mesomorphic phases (liquid crystals). Although crystalline materials are usually considered to

The relatively random arrangement of molecules in noncrystalline substances makes them poor coherent scatterers of X-rays, resulting in broad, diffuse maxima in diffraction patterns. Their X-ray patterns are quite distinguishable from crystalline specimens, which give sharply defined diffraction patterns.

Many compounds are capable of crystallizing in more than one type of crystal lattice. At any particular temperature and pressure, only one crystalline form (polymorph) is thermodynamically stable. Since the rate of phase transformation of a metastable polymorph to the stable one can be quite slow, it is not uncommon to find several polymorphs of crystalline pharmaceutical compounds existing under normal handling conditions.

In addition to exhibiting polymorphism, many compounds form crystalline solvates in which the solvent molecule is an integral part of the crystal structure. Just as every polymorph has its own characteristic X-ray patterns, so does every solvate. Sometimes the differences in the diffraction patterns of different polymorphs are relatively minor, and must be very carefully evaluated before a definitive conclusion is reached. In some instances, these polymorphs and/or solvates show varying dissolution rates. Therefore, on the time scale of pharmaceutical bioavailability, different total amounts of drug are dissolved, resulting in potential bioinequivalence of the several forms of the drug.

**Fundamental Principles**—A collimated beam of monochromatic X-rays is diffracted in various directions when it impinges upon a rotating crystal or randomly oriented powdered crystal. The crystal acts as a three-dimensional diffraction grating to this radiation. This phenomenon is described by Bragg's law, which states that diffraction (constructive interference) can occur only when waves that are scattered from different regions of the crystal, in a specific direction, travel distances differing by integral numbers (*n*) of the wavelength ( $\lambda$ ). Under such circumstances, the waves are in phase. This condition is described by the Bragg equation:

$$\frac{n\lambda}{2 \sin \theta} = d_{hkl}$$

in which  $d_{hkl}$  denotes the interplanar spacings and  $\theta$  is the angle of diffraction.

A family of planes in space can be indexed by three whole numbers, usually referred to as Miller indices. These indices are the reciprocals, reduced to smallest integers, of the intercepts that a plane makes along the axes corresponding to three non-parallel edges of the unit cell (basic crystallographic unit). The unit cell dimensions are given by the lengths of the spacings along the three axes, *a*, *b*, *c*, and the angles between them,  $\alpha$ ,  $\beta$ , and  $\gamma$ . The interplanar spacing for a specific set of parallel planes *hkl* is denoted by  $d_{hkl}$ . Each such family of planes may show higher orders of diffraction where the *d* values for the related families of planes *nh*, *nk*, *nl* are diminished by the factor 1/*n* (*n* being an integer: 2, 3, 4, etc.). Every set of planes throughout a crystal has a corresponding Bragg diffraction angle associated with it (for a specific  $\lambda$ ).

The amplitude of a diffracted X-ray beam from any set of planes is dependent upon the following atomic properties of the crystal: (1) position of each atom in the unit cell; (2) the respective atomic scattering factors; and (3) the individual thermal motions. Other factors that directly influence the intensities of the diffracted beam are: (1) the intensity and wavelength of the incident radiation; (2) the volume of crystalline specimen; (3) the absorption of the X-radiation by the specimen; and (4) the experimental arrangement utilized to record the intensity data. Thus, the experimental conditions are especially important for measurement of diffraction intensities.

Only a limited number of Bragg planes are in a position to diffract when monochromatized X-rays pass through a single crystal. Techniques of recording the intensities of all of the possible diffracting *hkl* planes involve motion of the single crystal and the recording media. Recording of these data is accomplished by photographic techniques (film) or with radiation detectors.

A beam passing through a very large number of small, randomly oriented crystals produces continuous cones of diffracted rays from each set of lattice planes. Each cone corresponds to the diffraction from various planes having a similar interplanar spacing. The intensities of these Bragg reflections are recorded

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.